Sugi Predict

Sugi Predict / Compounds / SCHEMBL1446409

SCHEMBL1446409

SCHEMBL1446409

Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(OC4CCOC4)cc23)cc1Cl

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 19/20 0.76
▸ ERBB2 P04626 6/20 0.76
▸ ERBB4 Q15303 4/20 0.76
▸ RET P07949 3/20 0.76
▸ KIT P10721 3/20 0.76
▸ SRC P12931 3/20 0.76
▸ ERBB3 P21860 3/20 0.76
▸ BRAF P15056 2/20 0.76
▸ CIT O14578 2/20 0.76
▸ GAK O14976 2/20 0.76
▸ EPHB6 O15197 2/20 0.76
▸ RIPK2 O43353 2/20 0.76
▸ STK17B O94768 2/20 0.76
▸ STK10 O94804 2/20 0.76
▸ ABL1 P00519 2/20 0.76
▸ LCK P06239 2/20 0.76
▸ LYN P07948 2/20 0.76
▸ MET P08581 2/20 0.76
▸ HCK P08631 2/20 0.76
▸ FGR P09769 2/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12743118 1.00 EGFR (0.76) EGFRERBB2ERBB4RETKIT
SCHEMBL1446406 1.00 EGFR (0.76) EGFRERBB2ERBB4RETKIT
SCHEMBL1446351 0.98 EGFR (0.73) EGFRERBB2ERBB4RETKIT
SCHEMBL1446353 0.98 EGFR (0.73) EGFRERBB2ERBB4RETKIT
SCHEMBL1446512 0.96 EGFR (0.76) EGFRERBB2ERBB4RETKIT
SCHEMBL1446516 0.96 EGFR (0.76) EGFRERBB2ERBB4RETKIT
SCHEMBL1446583 0.96 EGFR (0.80) EGFRERBB2ERBB4RETKIT
SCHEMBL12838693 0.96 EGFR (0.74) EGFRERBB2ERBB4RETKIT
SCHEMBL1446147 0.94 EGFR (0.76) EGFRERBB2ERBB4RETKIT
SCHEMBL12743048 0.93 EGFR (0.75) EGFRERBB2ERBB4RETKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8343982-B2 Bicyclic heterocyclic compounds pharmaceutical compositions containing these compounds, their use and process for preparing the same BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2013-01-01 — — US disclosed
US-20110077246-A1 BICYCLIC HETEROCYCLIC COMPOUNDS PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THE SAME BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) 2011-03-31 — — US disclosed
EP-2298305-A1 4-(N-Phenylamino)-quinazolines/quinolines as inhibitors of tyrosine kinases Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2011-03-23 — — EP disclosed
US-7910731-B2 Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2011-03-22 — — US disclosed
US-20090036676-A1 Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them HIMMELSBACH FRANK 2009-02-05 — — US disclosed
US-20060270672-A1 Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them HIMMELSBACH FRANK 2006-11-30 — — US disclosed
US-7119084-B2 Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-10-10 — — US disclosed
US-20050182043-A1 Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-08-18 — — US disclosed
US-6924285-B2 Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) 2005-08-02 — — US disclosed
US-20040048880-A1 Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-03-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270672-A1 Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them CYP11B2, CYP11B1, HPGD EGFR 1233/4885ERBB2 1107/4885ERBB4 2422/4885
US-20110077246-A1 BICYCLIC HETEROCYCLIC COMPOUNDS PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THE SAME CYP11B2, CYP11B1, PKD1 EGFR 1254/4885ERBB2 1199/4885ERBB4 2522/4885
US-20090036676-A1 Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them CYP11B2, CYP11B1, HPGD EGFR 1233/4885ERBB2 1107/4885ERBB4 2422/4885
US-20050182043-A1 Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them CYP11B2, CYP11B1, HPGD EGFR 1233/4885ERBB2 1107/4885ERBB4 2422/4885
US-20040048880-A1 Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them CYP11B1, AR, CYP11B2 EGFR 221/4885ERBB2 163/4885ERBB4 628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.